why choose us

First received: October 28, 2022

Clinical Trial: Low-dose Bevacizumab With HSRT vs BVZ Alone for GBM at First Recurrence

Study Status: Active, not recruiting

Recruit Status: Active, not recruiting

Condition: Glioma
Recurrent Glioma

Study Type: Interventional


Official Title: A Randomized Phase II Trial of Concurrent Low-dose Bevacizumab and HSRT Versus Bevacizumab Alone for Glioblastoma at First Recurrence: HSCK-005

Brief Summary: This randomized phase II trial studies how well lose dose bevacizumab with Hypofractionated Stereotactic Radiotherapy (HSRT) works versus bevacizumab alone in treating patients with glioblastoma at first recurrence. The primary endpoint is 6-month progress-free survivaloverall survival after the treatment. Secondary endpoints included overall survival, objective response rate, cognitive function, quality of life and toxicity.

Read more